Tresiba (Insulin Degludec) Monitoring for Young Adults (18, 29)

Why Monitoring Differs for Young Adults on Tresiba

Young adults aged 18 to 29 face a convergence of biological, behavioral, and psychosocial factors that make diabetes monitoring distinct from both pediatric and older adult protocols. Irregular sleep, alcohol use, shift work, and inconsistent meal timing all destabilize glucose control in ways that standard monitoring schedules may not catch.

The American Diabetes Association (ADA) 2024 Standards of Care specifically address emerging adults, noting that "the transition from pediatric to adult diabetes care is a high-risk period for loss of glycemic control and disengagement from care" 1. This age group experiences the highest rates of diabetic ketoacidosis (DKA) hospitalizations among all adult cohorts, with one CDC analysis reporting 30.7 DKA hospitalizations per 1,000 adults with type 1 diabetes aged 18 to 44 2. Tresiba's pharmacokinetic profile offers a partial buffer against these risks. Its 42-hour duration of action and flat glucose-lowering profile mean that a dose given 2 to 3 hours late produces less glycemic variability than the same delay would with insulin glargine U100 3. That flexibility does not replace monitoring. It changes what you should monitor and when.

HbA1c Targets and Testing Schedule

The ADA recommends an HbA1c target below 7.0% for most non-pregnant young adults with either type 1 or type 2 diabetes 1. For individuals planning pregnancy, the target drops to below 6.5%, ideally below 6.0% if achievable without significant hypoglycemia.

Test HbA1c every three months when initiating Tresiba or adjusting doses. Once glycemic targets are stable for two consecutive checks, the interval can extend to every six months. Young adults frequently resist quarterly lab draws, but framing each result as data rather than judgment improves adherence. Dr. Anne Peters, professor of medicine at the Keck School of Medicine at USC, has stated: "For young adults, the single best predictor of long-term outcomes is whether they stay connected to care at all. A missed A1c is more dangerous than a high A1c" 4.

HbA1c alone, though, misses glycemic variability. A young adult with an HbA1c of 7.2% could be spending 40% of the day above 250 mg/dL and another 10% below 54 mg/dL. The number looks acceptable while the pattern is dangerous. Pair HbA1c with CGM metrics for a fuller picture 5.

Continuous Glucose Monitoring and Time-in-Range Goals

CGM transforms monitoring for young adults on basal insulin by exposing the patterns that HbA1c and fingerstick logs cannot reveal. The 2019 International Consensus on Time in Range recommends targeting 70% or more of readings between 70 and 180 mg/dL, with less than 4% below 70 mg/dL and less than 1% below 54 mg/dL 5.

For young adults specifically, CGM data reveals three recurring problem patterns. First, late-night glucose rises from alcohol consumption. Alcohol suppresses hepatic gluconeogenesis initially, causing a dip, followed by a rebound hours later when the liver resumes glucose output against a backdrop of steady basal insulin. Second, dawn phenomenon amplification in those with irregular sleep-wake cycles. Third, exercise-induced hypoglycemia that may occur 6 to 12 hours after activity, often while sleeping.

The SWITCH 1 and SWITCH 2 crossover trials demonstrated that insulin degludec reduced the rate of overall symptomatic hypoglycemia by 30% (SWITCH 1, type 1, P=0.035) and 23% (SWITCH 2, type 2, P<0.05) compared to insulin glargine U100, with CGM confirmation of lower time-below-range 6. These findings argue for prioritizing CGM coverage in young adults on Tresiba, particularly during the first six months of therapy.

Review CGM ambulatory glucose profiles (AGP) every two to four weeks during dose titration. Focus on the overnight and early-morning windows, which reflect basal insulin performance most directly. A coefficient of variation (CV) above 36% signals problematic glycemic variability and may require dose splitting or mealtime insulin adjustment rather than simply increasing the Tresiba dose 5.

Hypoglycemia Surveillance

Hypoglycemia monitoring deserves its own protocol in this age group because young adults underreport low glucose events, often dismiss mild symptoms as normal fatigue, and may lose hypoglycemia awareness more quickly than older adults due to tighter targets and recurrent mild lows.

The DEVOTE trial (N=7,637) compared insulin degludec to insulin glargine U100 in patients with type 2 diabetes at high cardiovascular risk. Degludec showed a 53% lower rate of severe nocturnal hypoglycemia (rate ratio 0.47 to 95% CI 0.31 to 0.73, P<0.001) and a 40% lower rate of severe hypoglycemia overall (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) 7. While DEVOTE enrolled an older population (mean age 65), the mechanism behind this reduction (a flatter pharmacokinetic profile with lower peak-to-trough variability) applies across age groups.

For young adults, implement a structured hypoglycemia assessment at every clinic visit using these four questions: (1) How many times in the past two weeks did your glucose drop below 70 mg/dL? (2) Did any episodes occur while driving, exercising, or sleeping? (3) Did you need help from another person for any low? (4) Have you noticed any change in your ability to feel lows? Document responses consistently. A pattern of two or more nocturnal lows per month, even if mild, warrants a Tresiba dose reduction of 10 to 20% regardless of HbA1c.

Dose Titration and Adjustment Monitoring

Start Tresiba at 10 units once daily (or one-third of the total daily insulin dose when switching from another basal). Titrate by 2 units every three to four days based on fasting glucose, targeting 80 to 130 mg/dL before breakfast 8.

Young adults benefit from a simple, self-directed titration algorithm. The BEGIN trials established that patient-driven titration of insulin degludec produced equivalent HbA1c reductions compared to physician-driven adjustment, with a final mean dose of 0.38 U/kg in insulin-naive type 2 diabetes 9. Provide a written or app-based titration guide: if fasting glucose averages above 130 mg/dL over three days, increase by 2 units; if below 80 mg/dL, decrease by 2 units; if between 80 and 130, hold steady.

Monitor fasting glucose daily during active titration. Once the fasting target is met for two consecutive weeks, fasting checks can shift to three times weekly if CGM is in use. Without CGM, daily fasting glucose checks should continue indefinitely.

Injection site rotation affects absorption consistency. Degludec shows lower intra-individual variability than glargine U100 (CV of absorption: 20% for degludec vs. 68% for glargine U300 and 82% for glargine U100 in one pharmacodynamic study) 3. Remind young adults to rotate within a single body region (abdomen preferred) using a clock-face or grid pattern to avoid lipohypertrophy, which can alter absorption by 25% or more.

Laboratory Monitoring Beyond Glucose

Diabetes monitoring in young adults extends well beyond glucose control. The following labs form a baseline panel at Tresiba initiation, with repeat intervals adjusted by results.

Kidney function. Screen for diabetic kidney disease with a urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) annually. For type 1 diabetes, begin five years after diagnosis. For type 2, begin at diagnosis. The ADA emphasizes that "at least two of three UACR specimens collected within a 3- to 6-month period should be abnormal before considering a patient to have albuminuria" 1.

Lipids. Obtain a fasting lipid profile at baseline. If LDL is below 100 mg/dL and the patient has no additional cardiovascular risk factors, recheck every five years. If LDL exceeds 100 mg/dL or the patient has hypertension, smoking history, or family history of premature cardiovascular disease, recheck annually and consider statin therapy per the 2018 AHA/ACC guidelines 10.

Thyroid. Type 1 diabetes carries a 15 to 30% lifetime risk of autoimmune thyroid disease. Screen with TSH at diagnosis and every one to two years thereafter 11. Undetected hypothyroidism can masquerade as insulin resistance, leading to unnecessary dose escalation.

Retinal screening. Annual dilated eye exams begin at diagnosis (type 2) or within five years of diagnosis (type 1). Telemedicine-based retinal photography, now validated across multiple studies, improves screening rates in young adults who may skip in-person ophthalmology visits 1.

Fertility, Contraception, and Preconception Monitoring

Reproductive health monitoring is non-negotiable for young adults on insulin therapy. Approximately 50% of pregnancies in the United States are unplanned 12, making preconception counseling a standing agenda item at every visit for patients who could become pregnant.

The ADA recommends a preconception HbA1c below 6.5%, noting that "the risk of congenital malformations, preeclampsia, and macrosomia increases with HbA1c above this threshold" 1. Tresiba is classified as compatible with pregnancy use based on animal data, and the Novo Nordisk EXPECT registry has collected real-world pregnancy outcome data, though FDA labeling still advises individualized risk-benefit assessment 8.

For those not planning pregnancy, document contraception method and adherence at each visit. For those actively planning, add folate supplementation (at least 400 mcg daily), thyroid function testing, and retinal examination to the preconception workup. Tight glucose targets before conception require more aggressive CGM review, ideally every one to two weeks, to minimize hypoglycemia while lowering HbA1c.

For male patients, testosterone and gonadal function testing may be appropriate if symptoms of hypogonadism are present. Type 1 diabetes in young men is associated with lower testosterone levels in some cohort studies, and insulin resistance in type 2 diabetes is linked to hypogonadotropic hypogonadism 13.

Mental Health and Diabetes Distress Screening

Diabetes distress affects 18 to 45% of young adults with diabetes, depending on the screening tool used, and correlates directly with higher HbA1c and lower self-management adherence 14. The ADA Standards of Care recommend screening for diabetes distress, depression, and disordered eating at least annually using validated instruments such as the Diabetes Distress Scale (DDS) or the Problem Areas in Diabetes (PAID) questionnaire 1.

This is not peripheral to Tresiba monitoring. It is the monitoring. A young adult who skips insulin doses due to weight concerns, fear of hypoglycemia, or burnout will not benefit from any titration algorithm. Screen. Document. Refer when scores are elevated.

Dr. William Polonsky, president of the Behavioral Diabetes Institute, has noted: "Diabetes distress is not a psychiatric diagnosis. It is a normal response to an abnormal burden, and it requires clinical attention, not just encouragement" 14. Integrate a two-minute distress screen into every Tresiba follow-up visit.

Lifestyle Factors That Alter Monitoring Frequency

Young adults present monitoring challenges that older adults typically do not. Alcohol use, shift work, travel across time zones, and high-intensity exercise each require protocol modifications.

Alcohol. Binge drinking (defined as four or more standard drinks in two hours for women, five or more for men) suppresses hepatic glucose output for up to 24 hours. Patients who drink should check glucose before bed and set a CGM low alarm at 80 mg/dL rather than the standard 70 mg/dL. Tresiba's flat action profile reduces but does not eliminate alcohol-related nocturnal hypoglycemia risk.

Shift work. Rotating shifts disrupt circadian insulin sensitivity. A young adult working night shifts may need a 10 to 15% dose reduction on work nights compared to off nights. CGM data from at least two full shift rotations should guide this adjustment.

Exercise. Aerobic exercise lasting longer than 30 minutes can reduce insulin requirements for 24 to 48 hours. Resistance training typically causes a transient glucose rise followed by improved insulin sensitivity. Log exercise type, duration, and timing alongside CGM data to identify individualized patterns.

Travel. When crossing three or more time zones, Tresiba's 42-hour duration allows patients to simply take their next dose at the usual local time without bridging doses. Monitor fasting glucose daily during travel and for three days after return.

Building a Monitoring Schedule That Young Adults Will Follow

The best monitoring protocol is one the patient actually uses. For young adults on Tresiba, a practical minimum viable monitoring schedule includes daily fasting glucose (or CGM), HbA1c every three to six months, annual UACR plus eGFR, annual dilated eye exam or retinal photograph, fasting lipids at baseline then as indicated, TSH every one to two years for type 1, and diabetes distress screening annually. Clinicians should negotiate this schedule collaboratively, prioritize CGM access as the single highest-yield intervention, and anchor follow-up visits to existing routines (semester breaks, annual physicals, prescription refill appointments) rather than arbitrary calendar intervals.

Prescribe Tresiba FlexTouch pens rather than vials for this population. Pen-based dosing reduces dosing errors by 58% compared to syringe-and-vial in one crossover study 15, and the simpler workflow removes a barrier to adherence. Set the next appointment before the patient leaves the clinic.